SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma strengthens after approval from USFDA

29 Jul 2016 Evaluate

Ajanta Pharma is currently trading at Rs. 1746.40, up by 20.80 points or 1.21% from its previous closing of Rs. 1725.60 on the BSE.

The scrip opened at Rs. 1725.00 and has touched a high and low of Rs. 1776.75 and Rs. 1720.10 respectively. So far 27576 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1776.75 on 29-Jul-2016 and a 52 week low of Rs. 1103.00 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 1776.75 and Rs. 1601.70 respectively. The current market cap of the company is Rs. 15383.27 crore.

The promoters holding in the company stood at 73.78%, while Institutions and Non-Institutions held 12.06% and 14.16% respectively.

Ajanta Pharma has received final approval for Omeprazole and Sodium Bicarbonate Powder for Oral Suspension from USFDA. It is a bioequivalent generic version of Zegerid Powder for Oral Suspension and the company will be launching the product soon in 2 strengths 20 mg / 1680 mg & 40 mg / 1680 mg Powder Sachets.

This new approval is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 12 ANDAs; tentative approvals for 1 ANDA; and 13 ANDAs are under review with USFDA.

Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. The company is engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×